172 related articles for article (PubMed ID: 21289895)
1. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
Fröschl B; Brunner-Ziegler S; Hiebinger C; Wimmer A; Zsifkovits J
GMS Health Technol Assess; 2009 Jun; 5():Doc08. PubMed ID: 21289895
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
4. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres Ramírez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):287-298. PubMed ID: 30664365
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous S; Przech S; Martin J; Garg AX; Sarma S
Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
11. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
12. Safety of new phosphate binders for chronic renal failure.
Loghman-Adham M
Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
[TBL] [Abstract][Full Text] [Related]
16. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
[TBL] [Abstract][Full Text] [Related]
17. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR; Qunibi WY
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
[TBL] [Abstract][Full Text] [Related]
18. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
19. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
20. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
Spaia S
Hippokratia; 2011 Jan; 15(Suppl 1):22-6. PubMed ID: 21897754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
